Search Results

You are looking at 1 - 10 of 21 items for :

  • "GnRH agonist" x
  • Refine by Access: All x
Clear All
Full access

Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian

cardiovascular studies. A decade ago, the FDA mandated safety labels of gonadotropin-releasing hormone (GnRH) agonists to include additional warnings about potential increased risks for diabetes and cardiovascular events, and advocated for physicians to closely

Full access

Shinjini Ganguly, Zaeem Lone, Andrew Muskara, Anna Kondratova, Anthony Ghanem, Yoon-Mi Chung, Aimalie Hardaway, Monaben Patel, Elai Davicioni, Shilpa Gupta, Jay Ciezki, Jorge Garcia, Kevin Stephans, Rahul Tendulkar, Eric Klien, Nima Sharifi, and Omar Y. Mian

androgen directed therapy and nominates HSD3B1 genotype as a predictive biomarker of treatment response. An NCCN sponsored prospective validation cohort is currently accruing. Figure 1 Graphical Schema of HSD3B1’s role in GnRH agonist bypass and

Full access

Venkata K. Pokuri, Houman Nourkeyhani, Bodie Betsy, Laurie Herbst, Marcus Sikorski, Edward Spangenthal, Andrew Fabiano, and Saby George

difficult problems increasingly manageable, prompt recognition and the institution of adequate therapy are essential. Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists has remained the mainstay of prostate cancer

Full access

Philip J. Saylor and Matthew R. Smith

effective systemic treatment for prostate cancer. Whether accomplished through bilateral orchiectomies or treatment with a gonadotropin-releasing hormone (GnRH) agonist, ADT leads to severe hypogonadism. GnRH agonists, for instance, lower serum testosterone

Full access

therapy, eg, GnRH agonists, by converting circulating steroid precursors to androgens intracellularly. The rate limiting enzyme for this conversion is 3βHSD, which is stabilized by a common polymorphism (1245C). DHT biosynthesis downstreamof variant 3bHSD

Full access

Adrienne G. Waks and Ann H. Partridge

use of gonadotropin-releasing hormone (GnRH) agonists concurrent with chemotherapy. Use of GnRH agonists has been posited to improve the chances of ovarian recovery postchemotherapy through a variety of mechanisms, including decreasing ovarian and

Full access

Azeez Farooki

with various cancer therapies, including aromatase inhibitor (AI) therapy in postmenopausal women and AI therapy and gonadotropin-releasing hormone (GnRH) agonists in pre-menopausal women with breast cancer, bone marrow transplantation in patients with

Full access

Yan Hiu Athena Lee, Jiandong Zhou, Jeremy Man Ho Hui, Xuejin Liu, Teddy Tai Loy Lee, Kyle Hui, Jeffrey Shi Kai Chan, Abraham Ka Chung Wai, Wing Tak Wong, Tong Liu, Kenrick Ng, Sharen Lee, Edward Christopher Dee, Qingpeng Zhang, and Gary Tse

against all-cause mortality in younger patients. Subgroup Analysis by Use of ADT We analyzed the effect of ADT, including gonadotropin-releasing hormone (GnRH) agonists and antagonists, on all-cause mortality among metformin and sulfonylurea users

Full access

Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead, and Hema Sundar

investigational. Randomized trials that have evaluated the role of menstrual suppression with gonadotropin-releasing hormone (GnRH) agonists to preserve ovarian function during chemotherapy have provided conflicting reports. Three randomized trials showed that

Full access

Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey

tamoxifen); or (3) OA accomplished by outpatient laparoscopic bilateral salpingo-oophorectomy (BSO), followed by 5 years of an AI. We did not model the use of gonadotropin-releasing hormone (GnRH) agonist as a method of OA/AI, because there is no evidence